Entera Bio Ltd

5DT

Company Profile

  • Business description

    Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

  • Contact

    Minrav Building - Fifth Floor
    Kiryat Hadassah
    Jerusalem9112002
    ISR

    T: +972 25327151

    E: [email protected]

    https://www.enterabio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    22

Stocks News & Analysis

stocks

2 companies poised to capitalize on the rise of GLP-1 drugs

Why Pfizer and Roche look like top choices for investors in the war to tip the scales.
stocks

Does this bank have what it takes to compete with the big 4?

Organic growth and a recent acquisition were the focus of their investor day.
stocks

This ASX share is shrinking to greatness

A defensive opportunity for investors.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,915.0026.100.29%
CAC 408,108.436.31-0.08%
DAX 4024,046.0117.870.07%
Dow JONES (US)47,739.32215.67-0.45%
FTSE 1009,645.0921.92-0.23%
HKSE25,765.36319.72-1.23%
NASDAQ23,545.9032.22-0.14%
Nikkei 22550,581.9490.070.18%
NZX 50 Index13,512.1625.840.19%
S&P 5006,846.5123.89-0.35%
S&P/ASX 2008,624.4028.800.34%
SSE Composite Index3,924.0821.270.55%

Market Movers